- CancerNetwork.com
- CureToday.com
- OncLive.com
- TargetedOnc.com
- Privacy
- Terms & Conditions
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 52 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Latest from Moffitt Cancer Center
The Future of CAR T-Cell Therapy: Will Off-the-Shelf Options Soon Enter the Playing Field?
June 15, 2022
Article
Approval of off-the-shelf CAR T-Cell therapy options would provide greater accessibility and benefit to patients, say experts.
New Strategies Provide Faster Access To Cancer Care For Patients
May 27, 2022
Article
Pilot programs based out of Yale Cancer Center and Moffitt Cancer Center seek to improve access for newly diagnosed patients with cancer.
E-Selectin Represents Promising Direction for AML Treatment Focus
April 02, 2022
Article
Investigators are seeking to overcome barriers to help patients with acute myeloid leukemia achieve complete and durable remissions by focusing their attention on novel agents engineered to target adhesion factors.
Investigational CAR T-Cell Therapy, Obecabtagene Autoleucel, Is Poised to Fill Unmet Need in Relapsed/Refractory B-ALL
March 22, 2022
Article
Investigators hope that the novel obecabtagene autoleucel, a second-generation CAR T-cell therapy may fill an unmet need by representing a durable treatment option for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Investigators Seek to Evaluate Obe-Cel’s Role in Relapsed/Refractory B-Cell ALL
March 03, 2022
Article
An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.
Ask The Right Questions: Clinical Pearls of AE Management
February 15, 2022
Podcast
In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.